Searchable abstracts of presentations at key conferences in endocrinology

ea0026p80 | Endocrine tumours and neoplasia | ECE2011

Mitotane reduces the chemoresistance phenotype in an adrenocortical carcinoma cell line

Gagliano T , Robustelli A R , Mole D , degli Uberti E , Zatelli M C

Adrenocortical carcinoma (ACC), a rare tumor, with incidence of 1–2 per million population annually, has a bimodal distribution by age, with cases clustering in children under 6, and in adults 30–40 years old. ACC has a dismal prognosis. The only curative treatment is complete surgical excision of the tumor, but late diagnosis prevents surgical cure, since ACC frequently recurs and metastasize. Chemotherapy is frequently ineffective, due to the overexpression of the ...